Carl J. St. Bernard Appointed President and CEO of CeloNova

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

CeloNova BioSciences, Inc. today announced appointment of seasoned medical device executive Carl J. St. Bernard as President and Chief Executive Officer to support the company’s expected near-term commercial growth.

St. Bernard joins the company from Tryton Medical where he held the role of President and CEO, leading the company’s commercialization efforts in the highly competitive coronary stent market. St. Bernard also has an extensive track record growing businesses across a variety of fields including pharmaceuticals, consumer health products and diagnostic markets. St. Bernard’s prior experience includes Vice President at Johnson & Johnson Vision (formerly Abbott Medical Optics), Vice President of North American Marketing & Sales for LifeCell and Vice President at Cordis where he led the commercial operations for the cardiovascular and endovascular businesses in the U.S.

Jason Cone, who successfully served as CeloNova’s interim CEO for the past 2 years, will assume a position on the company’s Board of Directors. Under his leadership the company accomplished key commercial milestones and reached over 25,000 patients treated worldwide.

“Carl’s strong track record of commercial success and deep understanding of our customer’s needs is a huge asset as we broaden clinical adoption of COBRA PzF NCS across practices treating high-risk patients unable to tolerate long-term DAPT,” stated Mark Bates, MD, DSC, FACC, FSCAI, Director of the CAMC Cardiovascular Medicine Fellowship and Senior Scientist for Cardiovascular Research and Chairman of the Board at CeloNova. “We look forward to working with Carl to bring innovative cardiovascular treatments to patients around the world.”

The appointment of St. Bernard precedes the highly anticipated conclusion of the company’s COBRA REDUCE study, the world’s first and only randomized global trial evaluating ultra-short, 14-day dual-antiplatelet therapy (DAPT) compared to market-leading drug-eluting stents with 3 or 6 months DAPT in patients at high risk of bleeding.§^

Today, COBRA PzF NCS allows physicians to safely and effectively treat patients who may benefit from short, 1-month DAPT.1,2 In the PzF SHIELD IDE trial, COBRA PzF NCS with 1-month DAPT demonstrated 0% stent thrombosis, 4.6% total lesion revascularization at 9 month follow up.1,2 Low TLR and low ST with short DAPT has been consistently demonstrated across CeloNova’s comprehensive clinical trial program.3

“PCI patients at high risk for bleeding complications have long been a challenge for the interventional cardiology community,” stated St. Bernard. “COBRA PzF NCS is an innovative solution, unlike any other in the coronary stent market, that offers a safe and effective option for these patients. I look forward to leading CeloNova into its next phase of commercial growth.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.